Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
rituximab
Sponsor
Chinese University of Hong Kong